1. FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary Artery Lesions T. Lefèvre and W. Van der Giessen On Behalf the FRONTIER Investigators

2. Objective To assess the safety, procedural success, performance and 6 month clinical outcome of bifurcation stenting To evaluate angiographic results and 6 month incidence of TSR With the use of the Guidant MULTI-LINK FRONTIER  Coronary Stent System in patients with de novo or restenotic bifurcation lesions

3. Study design Prospective, non randomized 100 patients Up to 2 lead in patients per site 13 sites - Europe, New Zealand Clinical Follow-up In-hospital, 30 days and 6 months Angiography Pre and Post-Procedure 6 months

4. Specially designed dual lumen tip Main Branch (RX) Side Branch (OTW) Designed for preserving side branch access Integrated-tip design allows single tip delivery, avoiding wire wrap Stent deploys with simultaneous “kissing balloon inflation” Wire position is maintained in both branches throughout the procedure Guidant MUTI-LINK FRONTIER™ Coronary Bifurcation Stent System

5. Guidant ML FRONTIER™ Coronary Bifurcation Stent System Sizes Stent length – 18mm (main branch) 7 Fr. GC Compatible Main Branch Balloon2.5mm3.0mm3.5mm4.0mm Side Branch Balloon2.0mm2.5mm

6. Two balloons. Two wires. One very special stent. “Provisional T stenting” strategy Guidant MULTI-LINK FRONTIER™ Deployment Technique

7. ML FRONTIER™ Deployment Sequence Guidant MULTI-LINK FRONTIER™ Deployment Technique Self rotation when out of phase

8. Primary endpoints Incidence of MACE* at 6 months follow-up * Hierarchical occurrence of Death, Q-wave and non-Q-wave MI, Target Lesion Revascularization (main branch and/or side branch) including PTCA and CABG

9. Secondary endpoints Incidence of MACE at 30 days follow up Angiographic binary restenosis rate at 6 months Access site complications TVF at one and six months follow up TVR at six months follow up Acute success of stent delivery, deployment, and post dilatation

10. Key Inclusion Criteria Other lesions in different epicardial vessel successfully treated prior to bifurcation procedure Native or restenotic (no stent) vessel suitable to receive a 2.5 to 4.0 mm ML FRONTIER  Stent Target main branch vessel is a major coronary artery with estimated stenosis > 50 and < 100% Angle of bifurcation < 75  Main branch lesion suitable for a total stent length of < 31mm by visual estimate Appropriate lesion morphology

11. Key Exclusion Criteria Untreated lesion >50% proximal or distal to target lesion Target lesion contains thrombus Target lesion is aorto-ostial or left main stem location Target lesion or proximal vessel has excessive tortuosity unsuitable for stent delivery Heavy or severe calcification

12. Enrolling Sites (n= 11) Patients enrolled Dr. van der GiessenRotterdamThe Netherlands16 Dr. OrmistonAucklandNew Zealand15 Prof. SchultheissBerlinGermany15 Dr. QuilletToursFrance12 Dr.ReimersMiranoItaly11 Dr. LefèvreMassyFrance10 Dr. GuagliumiBergamoItaly9 Dr. BrunelNantesFrance7 Dr. WijnsAalstBelgium6 Dr. BüttnerBad KrozingenGermany2 Dr. HartmannLübeckGermany2 Total105

13. FRONTIER Trial Enrollment

14. Baseline Demographics (Intent-to-treat patient population) n = 105 Age (years)62.4 (60.3 – 64.5) Number of men (%)77.1 Current smoker (%)27.9 Diabetes requiring treatment (%)17.1 Hypertension requiring treatment (%)46.2 Hypercholesterolemia requiring treatment (%)64.8 Prior MI (%)36.2 Stable angina: CCS III or IV (%)14.3 Unstable angina: Braunwald class 1-2 A-B (%)30.5 Prior CABG (%)1.0 LAD location (%)79.1

15. Baseline QCA Analysis (Intent-to-treat patient population) Target vessel (n= 103 patients*) Main branch (%) Side branch (%) Moderate to heavy Calcification29.411.7 Thrombus1.90 Pre-procedural TIMI flow Grade 391.393.2 ACC / AHA lesion class A2.026.6 B120.860.9 B277.212.5 * Cardialysis, Rotterdam, The Netherlands

16. Bifurcation Lesion Classification (Intent-to-treat patient population) Bifurcation angulation < 75 degrees70.9% 7.9%24.8% 13.9% 36.6% 5.9% 10.9% Prebranch Postbranch Parent Vessel Only Bifurcation Ostial Prebranch and ABC DEF Cardialysis, Rotterdam, The Netherlands

17. Device success*92.2% Procedural success93.3% Use of GPIIb/IIIa inhibitors26.0% Additional stent implant - One only - More than one 37.1% 6.7% Reason why additional stent implanted - To cover target lesion - Inflow dissection - Outflow dissection 16.7% 66.7% 16.7% Stent used - Diameter (mm) - Length (mm) 3.03 ± 0.37 12.51 ± 5.57 Procedural data in Main Branch (Intent-to-treat patient population) * Stent did not cross (8/9), twisted wire (1/9)

18. Device success*92.2% Procedural success93.3% Use of GPIIb/IIIa inhibitors26.0% Additional elective stent implant as allowed by protocol (n) 37.1% (39/105) More than one additional stent (n) ** -To cover target lesion (n) -Inflow dissection (n) - Outflow dissection (n) 6.7% (7/105) 1 4 1 Stent used - Diameter (mm) - Length (mm) 3.03 ± 0.37 12.51 ± 5.57 Procedural data in Main Branch (Intent-to-treat patient population) * Stent did not cross (8/9), twisted wire (1/9) ** 1 reason unknown Caution: Investigational device. Limited by Federal (US) law to investigational use only. Not available for sale

19. Pre-procedure reference vessel diameter (mm)2.77 ± 0.51 Lesion length (mm)12.16 ± 5.83 Pre-dilatation performed (%) Maximum pre-dilatation balloon size: - Diameter (mm) - Length (mm) - Balloon pressure (atm) 100 2.68 ± 0.40 16.25 ± 3.77 10.36 ± 3.13 FRONTIER stent max. deployment pressure (atm)12.1 ± 2.3 Post stent implant dilatation performed (%) Maximum post-dilatation balloon size: - Diameter (mm) - Length (mm) - Balloon pressure (atm) 70.8 3.14 ± 0.45 13.43 ± 4.03 11.9 ± 3.80 Procedural data in Main Branch (Per protocol patient population) Cardialysis, Rotterdam, The Netherlands

20. Lesion length (mm)4.03 ± 2.71 Pre-procedure reference side branch diameter (mm)2.10 ± 0.67 Side branch post treatment - None (%) - Balloon (%) - Stent (%) 19.8 37.5 42.7 Stent diameter (mm)2.64 ± 0.34 Stent length (mm)9.92 ± 2.81 Maximum balloon diameter (mm)2.53 ± 0.44 Maximum balloon length (mm)15.03 ± 4.59 Maximum balloon pressure (atm)10.15 ± 2.81 Kissing balloon technique performed (%)79.5 Procedural data in Side Branch (Per protocol patient population) Cardialysis, Rotterdam, The Netherlands

21. Main Branch In-stent (n = 96) Pre-procedure ref. diameter (mm)2.77 ± 0.51 Pre-procedure DS (%)60.7 ± 12.2 Pre-procedure MLD (mm)1.07 ± 0.35 Post-procedure DS (%)15.1 ± 9.6 Post-procedure MLD (mm)2.43 ± 0.41 6-month DS (%)38.8 ± 19.1 6-month MLD (mm)1.59 ± 0.56 Binary restenosis (>50%)25.3 % Acute gain in-stent (mm)1.36 ± 0.46 Late loss in-stent (mm)0.84 ± 0.55 QCA Analysis (Per-protocol patient population) In-stent + 5 mm (n=96) - - - 24.5 ± 9.5 2.04 ± 0.40 40.3 ± 19.29 1.51 ± 0.54 27.6 % - - Cardialysis, Rotterdam, The Netherlands

22. Side Branch In-segment Total (n = 96) Pre-procedure ref. diameter (mm)2.10 ± 0.67 Pre-procedure DS (%)39.1 ± 18.1 Pre-procedure MLD (mm)1.23 ± 0.45 Post-procedure DS (%)25.1 ± 12.7 Post-procedure MLD (mm)1.47 ± 0.40 6-month DS (%)39.4 ± 20.9 6-month MLD (mm)1.13 ± 0.47 Binary restenosis (>50%)29.1 % QCA Analysis (Per-protocol patient population) Stented (n = 39) Ballooned (n = 36) Non-treated (n = 21) 2.32 ± 0.792.01 ± 0.531.81 ± 0.54 46.7 ± 19.437.0 ± 13.927.4 ± 15.1 1.17 ± 0.461.27 ± 0.441.30 ± 0.43 23.8 ± 12.727.3 ±11.723.6 ± 14.6 1.59 ± 0.421.42 ± 0.371.30 ± 0.36 44.8 ± 26.233.9 ± 14.037.6 ± 15.2 1.02 ± 0.561.24 ± 0.351.19 ± 0.40 36.8 %18.8 %31.3 %

23. MACE (intent-to-treat patient population) In-Hospital n=105 30 ± 5 days n=105 SAT (%) Q-wave MI (%) Non Q-wave MI (%) 01.0 1.0 TLR, CABG or PCI (%)1.0 TVR, CABG or PCI (%)1.0 Death (%) (Death, MI, TLR) 00 MACE (%)2.9 Target Vessel Failure (%) (Death, MI, TVR) 2.9 Hierarchical Ranking 180 ± 10 days n=105 01.9 13.4 19.1 0 17.1 22.9

24. Sample calculation (MACE) Study Alpha Rate nLower Limit Upper Limit Finci et al0.0537.4% 91 27.4% 48.1% Yamashita et al0.0537.8% 37 22.5% 55.2% Finci et ali 0.0562.2% 45 46.5% 76.2% Yamashita et al0.0550.9% 53 36.8% 64.9% Lefèvre et al0.0529.1% 182 17.5% 36.3% Karvouni et al0.0548.4% 62 35.5% 61.4% Al Suwaidi et al 0.0526.8% 75 17.1% 38.1% Al Suwaidi et al0.0547.7% 51 32.9% 61.5% Wt. Avg 29.5%51.2 %

25. Conclusion This new stent specifically designed for treating bifurcation lesions and preserving side branch access can be used with a high procedural success rate. Compared to previous studies with workhorse stents, the clinical outcome as well as acute angiographic and 6-months results are very encouraging.